3-羟基-2-吡咯烷酮
3-羟基-2-吡咯烷酮 性质
| 储存条件 | Sealed in dry,Store in freezer, under -20°C |
|---|---|
| 溶解度 | DMSO:89.5(最大浓度 mg/mL);226.14(最大浓度 mM) 乙醇:11.0(最大浓度 mg/mL);27.79(最大浓度 mM) |
| 形态 | 结晶固体 |
3-羟基-2-吡咯烷酮 用途与合成方法
| Target | Value |
|
HBV capsid
(Cell-free assay) | 53 nM |
BAY 41-4109 is able to both accelerate and misdirect capsid assembly in vitro . Preformed capsids are stabilized by BAY 41-4109, up to a ratio of one inhibitor molecule per two dimers. BAY 41-4109 is equally effective at inhibiting HBV DNA release and the cytoplasmic HBcAg level, with IC 50 s of 32.6 and 132 nM in HepG2.2.15 cells, respectively. HBV DNA and HBcAg are inhibited in a dose-dependent manner, indicating that the anti-HBV mechanisms are associated with and dependent on the rate of HBcAg inhibition.
BAY 41-4109 reduces viral DNA in the liver and in the plasma dose-dependently with efficacy comparable to 3TC. BAY 41 -4109 reduces hepatitis B virus core antigen (HBcAg) in livers of HBV-transgenic mice. Pharmacokinetic studies in mice have shown rapid absorption, a bioavailability of 30% and dose-proportional plasma concentrations, about 60% in rats and dogs.BAY41-4109 inhibits virus production in vivo by a mechanism that targets the viral capsid.
3-羟基-2-吡咯烷酮 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-04-30 | HY-100029A | 1 mg | 266 | ||
| 2024-04-30 | HY-100029A | 3-羟基-2-吡咯烷酮 | 298708-79-9 | 5mg | 700 |
